PROCEPT BioRobotics officer to sell 373 shares
PROCEPT BioRobotics Corp (PRCT) has a notice under Rule 144 indicating that officer Kevin Waters may sell up to 373 shares of the company’s common stock through Fidelity Brokerage Services LLC on NASDAQ.
Rhea-AI Filing Summary
PROCEPT BioRobotics Corp (PRCT) has a notice under Rule 144 indicating that officer Kevin Waters may sell up to 373 shares of the company’s common stock through Fidelity Brokerage Services LLC on NASDAQ.
The shares relate to restricted stock that vested on September 8, 2026, and the planned sale includes an amount to cover a tax obligation arising from the settlement of this vested equity award.
Positive
- None.
Negative
- None.
Key Figures
Shares covered by Rule 144 notice: 373 shares
Planned sale date: September 9, 2026
Restricted stock vesting date: September 8, 2026
3 metrics
Shares covered by Rule 144 notice
373 shares
Maximum number of PROCEPT BioRobotics common shares to be sold for Kevin Waters’ account
Planned sale date
September 9, 2026
Approximate date of sale for the shares covered by the notice
Restricted stock vesting date
September 8, 2026
Date the restricted stock underlying the planned sale vested as compensation
Key Terms
Rule 144, Restricted Stock Vesting, vested equity award, attorney-in-fact
4 terms
Rule 144 regulatory
"See the definition of "person" in paragraph (a) of Rule 144"
Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.
Restricted Stock Vesting financial
"Common | 09/08/2026 | Restricted Stock Vesting | Issuer"
Restricted stock vesting is the timetable and conditions under which shares granted to employees or insiders become fully owned and can be sold, typically requiring continued work or meeting performance goals. It matters to investors because large blocks of shares can become tradable at once, which can change share supply and price, and because vesting aligns insiders’ incentives with the company’s long‑term performance—think of it like a timed unlock that both rewards and locks in key people.
vested equity award financial
"resulting from the settlement of a vested equity award distribution"
attorney-in-fact regulatory
"as attorney-in-fact for Kevin Waters"
An attorney-in-fact is the person or entity given legal authority through a power of attorney to act on behalf of another for specific tasks, such as signing documents, voting shares, or handling transactions. For investors, this matters because it lets a trusted representative make timely decisions or complete paperwork when the owner cannot, much like handing keys to someone to run errands on your behalf—so checks on scope and limits of that authority are important.
FAQ
What does the Form 144 notice for PRCT disclose about Kevin Waters’ planned sale?
The notice shows that officer Kevin Waters may sell up to 373 shares of PROCEPT BioRobotics common stock under Rule 144, with sales to be executed through Fidelity Brokerage Services LLC on NASDAQ.
Which broker and exchange are involved in the PRCT Rule 144 sale for Kevin Waters?
The planned Rule 144 sale for Kevin Waters’ PRCT shares is through Fidelity Brokerage Services LLC, with the common stock listed for trading on NASDAQ.
AI-generated analysis. How Rhea-AI works. Not financial advice.